Skip to content

Syndax Pharmaceuticals

US · SNDX #2947 by market cap Listed 2016
8.72 -0.41 -4.49%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 9.04 -0.99%
After-hours 8.72 0.00%
Overnight 8.25 -9.64%
24.848.568.722026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on SNDX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -52.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 21.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 96.0% Better than 98%
Operating margin -158.4% Better than 6%
Net margin -165.6% Better than 6%
Return on equity -161.8% Better than 4%
Return on invested capital -148.9% Better than 1%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -55.6% Better than 4%
6-month return -56.3% Better than 5%
12-month return (ex latest month) -22.2% Better than 13%
Distance below 52-week high 65.9% Better than 8%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.4x Better than 83%
Debt to assets 0.3% Better than 97%
Interest coverage -7.4x Better than 14%
Free cash flow / net income 116.4% Better than 49%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 83.3% Better than 63%
Upside to average target 332.0% Better than 98%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.72%
1M -34.19%
3M -55.85%
6M -56.68%
YTD -58.50%
1Y -48.86%
3Y -43.45%
5Y -50.90%

Key statistics

Price & volume

Prev close
9.13
Open
9.07
Day range
8.69 - 9.27
Avg price
8.88
Volume
2.18M
Turnover
19.38M
Amplitude
6.35%
52-week range
8.41 - 25.59

Valuation

P/E
-2.65
P/E (TTM)
-3.68
P/B
-45.65
EPS
-3.29
Net profit
-296.19M
Net assets
-17.20M

Share structure

Market cap
785.05M
Float cap
707.10M
Shares out
90.03M
Float shares
81.09M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-03-03
52-week range 2% of range
8.41 25.59

65.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-29.26M net over the window

Short interest

Shares short
18.92M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Syndax Pharmaceuticals (SNDX)?

Syndax Pharmaceuticals last traded at 8.72. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Syndax Pharmaceuticals's market cap?

About 785.05M.

What is the P/E ratio of Syndax Pharmaceuticals?

The trailing twelve-month P/E is -3.68, below its own 5-year average of 5.07 — in the middle of its historical range (65.95% percentile). See the Valuation tab for the full history.

Does Syndax Pharmaceuticals pay a dividend?

Syndax Pharmaceuticals does not currently pay a regular dividend.

Is Syndax Pharmaceuticals a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 37.67, which implies 332.0% upside from the current price. This is not investment advice.

What is Syndax Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Syndax Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Syndax Pharmaceuticals discussion 0 comments

Add a comment